FDA Previews New Drug-Eluting-Stent Guidance At CRT Meeting In D.C.
This article was originally published in The Gray Sheet
Executive Summary
FDA's upcoming drug-eluting-stent guidance will emphasize long-term safety and shift the focus of trials from surrogate to clinical endpoints